Current Report Filing (8-k)
November 19 2019 - 8:22AM
Edgar (US Regulatory)
00-0000000 false 0001674416 0001674416 2019-11-19 2019-11-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 19, 2019
CRISPR THERAPEUTICS AG
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
|
Switzerland
|
|
001-37923
|
|
Not Applicable
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
Baarerstrasse 14
6300 Zug, Switzerland
|
|
Not Applicable
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including Area Code: +41 (0)41 561 32 77
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Shares, CHF 0.03 par value
|
|
CRSP
|
|
NASDAQ Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 7.01.
|
Regulation FD Disclosure.
|
On November 19, 2019, CRISPR Therapeutics AG (the “Company”) issued a press release announcing interim data from the first two patients treated with CTX001® in ongoing Phase 1/2 clinical trials. A copy of the press release is attached hereto as Exhibit 99.1.
The information in this Item 7.01 of Form 8-K, including the accompanying Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.
On November 19, 2019, the Company hosted a conference call and webcast to discuss interim data from the first two patients treated with CTX001 in ongoing Phase 1/2 clinical trials. A copy of the presentation slides used by the Company during the conference call and webcast is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
CRISPR THERAPEUTICS AG
|
|
|
|
|
|
|
|
|
|
Date: November 19, 2019
|
|
|
|
By:
|
|
/s/ Samarth Kulkarni
|
|
|
|
|
|
|
|
Samarth Kulkarni, Ph.D.
|
|
|
|
|
|
|
|
Chief Executive Officer
|
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Mar 2024 to Apr 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Apr 2023 to Apr 2024
